ClinicalTrials.gg

Program

ART5803

A development code. Also written as “ART5803-Cohort D”.

Its studies are mostly in Autoimmune Diseases of the Nervous System · Encephalitis, led by 2 companies.

Furthest: phase 2, since Aug 15, 20243 company-led studies, 1 open or runningNext primary completion: Nov 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Arialys Therapeutics20 open or runningphase 1since Aug 15, 2024Aug 15, 2024none ahead
Arialys Australia Pty11 open or runningphase 2since Jun 19, 2025Jun 19, 2025Nov 30, 2027phase 2 · NCT07093333

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 15, 2024First study: phase 1 study in Autoimmune Diseases of the Nervous SystemNew to Arialys TherapeuticsArialys Therapeutics · NCT06575153 · 64 enrolled · Australia
  2. Dec 23, 2024Phase 1 study in Autoimmune Diseases of the Nervous SystemArialys Therapeutics · NCT06753955 · 7 enrolled · Australia
  3. Jun 19, 2025Arialys Australia Pty's first study: phase 2 study in EncephalitisNew to Arialys Australia PtyArialys Australia Pty · NCT07093333 · 30 planned · South Korea

Ahead

  1. Nov 30, 2027Primary completion: phase 2 study in EncephalitisArialys Australia Pty · NCT07093333

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07093333Encephalitis · South Korea2RecruitingArialys Australia PtyNov 30, 202730
NCT06753955Autoimmune Diseases of the Nervous System · Australia1CompletedArialys TherapeuticsJul 2, 20257
NCT06575153Autoimmune Diseases of the Nervous System · Australia1CompletedArialys TherapeuticsSep 11, 202564

How it is read

Names in the registry

  • “ART5803”, 3 entries
  • “ART5803-Cohort D”, 1 entry

Codes read as this program: ART5803.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.